Good MorningEquity markets pulled back for Wednesday's 3rd day this week as a growing fear of an economic downturn saps bullish sentiment. The downturn, which has been expected for several quarters, appears to be finally here based on guidance from retailers like Target and Lowe's. In their view, consumer spending will fall double-digit this year, on top of a 30% correction in the housing market—demand for mtg fells to a 28-year low and points to a deepening correction in that sector.
On the bright side, not all is lost in the investing world. While most of the S&P 500 index is under pressure, some sectors, like fast food, are producing growth and guiding for growth in 2023. These stocks offer investors a range of opportunities, including blue chip safety, high yield, and value, depending on where you look. Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Industrials | |
Plug Power’s (NASDAQ: PLUG) Q4 and FY results have the shares moving sharply lower, but this is a knee-jerk reaction to headline news. The results were weaker than expected but should not have been a surprise given the early phase of the business. Start-ups across sectors, industries, and ve... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Auto/Tires/Trucks | |
Shares of Rivian Automotive, Inc. (NASDAQ: RIVN) are down more than 17% the day after the company delivered a disappointing earnings report. The results were mixed and not altogether poor, but they were still enough to give investors a taste of consumers' anxiety about electric vehicles.
Rivian ... Read the Full Story |
|
Retail/Wholesale | |
Target Corporation’s (NYSE: TGT) shares were down more than 4% in Wednesday’s session, despite the retailer beating the headline expectations in their earnings report yesterday. As initial reactions go to quarterly updates, you’d be forgiven for thinking it was an odd one, but on... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Technology | |
A high dividend yield can be an attractive feature, as it’s a way of gauging a stock’s dividend payout relative to its price. Some of the highest yields can be found in oil-and-gas master limited partnerships and tanker companies, but you can also get high yields from many other sector... Read the Full Story |
|
Consumer Discretionary | |
Jack in the Box (NASDAQ: JACK) CEO Darrin Harris has this company wound up and ready to spring into growth. He has been rationalizing operations across the system, focusing on building the franchise network and growing into new markets. His efforts include menu choices and standardizations, a push... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Retail/Wholesale | |
If you are wondering how low Lowe’s Companies (NYSE: LOW), or Home Depot (NYSE: HD), can go, the answer is a lot lower. The charts are set up to suggest a generational-quality pullback is underway in these blue-chip dividend payers, which is good news for long-term investors. Current stockho... Read the Full Story |
|
Technology | |
Ambarella (NASDAQ: AMBA) has had its share of ups and downs, but it has always come out of its slumps in a better position than before. Today’s issues are inventory-related, with the Q4 results and 2023 outlook at less-than-expected levels. The takeaway from the report is that inventory leve... Read the Full Story |
|
Retail/Wholesale | |
Wendy’s (NASDAQ: WEN) and McDonald’s (NYSE: MCD) are not the same sizes but on equal footing in many ways. Both companies produce double-digit growth, trade about 25X their earnings, and pay relatively safe and attractive dividends. The difference is that Wendy’s produced double-... Read the Full Story |
|
Markets | |
Terran Orbital Co. (NYSE: LLAP) makes and operates small satellites for the defense and aerospace industries. Its stock spiked over 80% on the news of being awarded a $2.4 billion contract. Its wholly owned subsidiary Tyvak Nano-Satellite Systems received $2.4 billion from Rivada Space Networks to... Read the Full Story |
|
Consumer Staples | |
In a down month for U.S. equities, General Mills, Inc. (NYSE:GIS) bucked the tide in February 2023. It’s something the packaged foods maker has grown quite accustomed to.
In 2022, when the S&P 500 suffered its worst year since 2008, General Mills ran 24%. Part of it was investors seekin... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. | | View Today's Stock Pick |
|
